# Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

> **NCT00195325** · PHASE1 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 45 (—)

## Conditions studied

- Tumors
- Neoplasms

## Interventions

- **DRUG:** TTI-237

## Key facts

- **NCT ID:** NCT00195325
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 45 (—)
- **Last updated:** 2007-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195325, "Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT00195325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*